U.S. Luxury Stock News

UroGen Pharma (URGN) drew fresh investor attention after submitting a New Drug Application to the FDA for UGN-103, supported by Phase 3 UTOPIA trial data in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. See our latest analysis for UroGen Pharma. The NDA news lands after a strong run for UroGen Pharma, with a 30-day share price return of 14.38%, a 90-day share price return of 62.20%, and a 1-year total shareholder return of 141.05% that signals building momentum...

Liquidia Corporation recently reported past second-quarter 2026 results showing revenue of US$171.68 million versus US$8.84 million a year earlier, with net income of US$74.72 million replacing a prior net loss and basic earnings per share from continuing operations rising to US$0.84. Over the first half of 2026, this shift from losses to profits and strong revenue expansion underscores how YUTREPIA’s commercialization and improved payer access are now translating more fully into the...

Deluxe (DLX) is back in focus after appointing Kevin Jones as President of its Merchant Services division, shortly after acquiring his company Celero Commerce. This acquisition helped position Deluxe as a top-10 non-bank merchant acquirer. See our latest analysis for Deluxe. Investors have seen Deluxe’s share price give back some ground recently, with a 1-month share price return that declined 9.26% and a 7-day share price return that declined 1.83%. However, the year-to-date share price...

Align Technology (ALGN) continues to draw investor attention after recent share price moves, with the stock last closing at $162.55. The company reported annual revenue of $4.14b and net income of $413.58m. See our latest analysis for Align Technology. Recent trading has been choppy for Align Technology, with a 1-day share price return of 2.27% following a 7-day share price decline of 10.35%, while the 1-year total shareholder return of 8.68% contrasts with a 3-year total shareholder return...

With US and Canada trade talks breaking down and fresh tariffs set to hit everything from steel to farm gear, investors are staring at a reshaped playing field where cross border supply chains may face higher costs and fresh uncertainty. That kind of disruption can punish some stocks yet open doors for others that lean on domestic production. This article walks through three stocks exposed to the latest tariff news and explains how they might fit into your watchlist. The stocks highlighted...

Westinghouse Air Brake Technologies (WAB) is back in focus after reporting quarterly earnings that exceeded expectations. The results were supported by higher sales and improved operating margins, and the company also raised full-year guidance for adjusted earnings and revenues. See our latest analysis for Westinghouse Air Brake Technologies. That earnings surprise lands on top of a strong run for Westinghouse Air Brake Technologies, with a 16.05% 90 day share price return and a 37.59% year...

Microchip Technology has delivered a 17.0% gain year to date, yet the stock now screens as expensive, with both its Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples pointing to a premium price tag. For investors, that combination raises the question of how much of the company’s recent product progress in areas like space grade timing and edge AI connectivity is already reflected in the share price. The 17.0% year to date return can signal growing optimism around...

Nucleai recently announced an ongoing translational research collaboration with Gilead Sciences, using AI-driven tissue analytics on large H&E and IHC slide datasets to support Gilead’s global antibody-drug conjugate clinical development programs across multiple oncology indications. The work has already produced candidate spatial biomarkers and fresh biological insights, highlighting how AI-native tissue intelligence could help standardize biomarker assessment and better link tumor biology...

WEX (WEX) shares were in focus after the company reported second quarter 2026 results that beat earnings and revenue estimates, raised full year guidance, and outlined plans to prioritize share repurchases. See our latest analysis for WEX. WEX shares trade at US$199.93, with a 1-month share price return of 13.5% and a 90-day share price return of 32.8%, while the 1-year total shareholder return sits at 15.6%, indicating recent positive momentum following earnings and guidance. If strong...

Packaging Corporation of America (PKG) drew fresh investor attention after reporting second quarter 2026 adjusted earnings above consensus, supported by higher production, stronger sales volumes, and contributions from its recent Greif acquisition. See our latest analysis for Packaging Corporation of America. Packaging Corporation of America’s recent earnings beat and Greif integration come after a strong run, with a 19.74% year to date share price return and a 93.51% five year total...

Kahn Swick & Foti, LLC recently continued its investigation into The Scotts Miracle-Gro Company over potential fiduciary breaches after 2023 results revealed a 6% sales decline, a 420 basis point gross margin reduction, a 25% cut to full-year EBITDA guidance, and a US$20,000,000 inventory write-down. These disclosures have already led to a securities class action lawsuit alleging failures to share material information, putting Scotts Miracle-Gro’s governance, disclosure practices, and risk...

With a fresh US–Canada trade clash pushing tariffs higher and rattling cross border supply chains, investors face a new map of potential winners and losers. Sudden shifts in costs and sourcing can reshape where production happens and which companies keep pricing power. This article walks through three stocks from our U.S. Onshoring and Domestic Manufacturing Beneficiaries screener that appear well positioned for this moment. The stocks highlighted below are just a starting sample, and the...

Omeros (OMER) is in focus after reporting a shift to net income in its second quarter and first half of 2026, replacing prior year losses and prompting fresh attention on the stock. See our latest analysis for Omeros. That shift to profit has coincided with sharp share price momentum for Omeros, with a 96.83% 1 month share price return and a 68.15% 3 month share price return. This has contributed to a very large 1 year total shareholder return. If strong recent gains in Omeros have you...

Why Illumina’s New Financing Matters For Stock Investors Illumina (ILMN) has just put in place a new US$1b senior unsecured revolving credit facility and completed a roughly US$300m fixed income offering. These financing steps give investors fresh information on the company’s balance sheet flexibility. The new credit agreement runs for five years, with options to extend to 2031. It replaces Illumina’s prior facility that was terminated on 13 August 2026. As of that date, the company reported...

CME Group has moved to broaden its derivatives line-up, introducing index-based Hockey futures, AI compute rental futures tied to GPU costs, and 24/7 trading for its 100‑Ounce Silver contract, alongside previously launched 1‑Ounce Gold weekend trading. Together, these launches extend CME’s reach into sports, AI infrastructure, and retail-friendly precious metals trading, highlighting how exchange-style risk management is being applied to increasingly unconventional underlying markets. We’ll...

In August 2026, CACI International Inc. opened a 61,000-square-foot Manufacturing Center of Excellence for Defense Electronics near Rochester, New York, expanding its production footprint for advanced electronic warfare technologies and supporting the U.S. Army’s Terrestrial Layer System Brigade Combat Team Manpack program. Alongside this capacity build-out, CACI International Inc. was selected as one of 15 awardees on the US$981 million NITE-STAR IDIQ with the U.S. Space Force, underscoring...

Healthcare Services Group (HCSG) is back on investor radars after its Zacks Rank shifted to Strong Buy, alongside a 12.9% upward move in the full-year earnings consensus over the past quarter. See our latest analysis for Healthcare Services Group. At a share price of US$22.77, Healthcare Services Group has seen short term momentum cool slightly after a 1-day share price return that declined 1%, although a 90-day share price return of 11.45% and 1-year total shareholder return of 44.34% point...

Pictet Asset Management SA’s decision to engage with Elastic (NYSE:ESTC) on August 20, 2026, puts fresh attention on the company’s business practices and potential implications for long term shareholder value. See our latest analysis for Elastic. Elastic’s recent share price move to US$85.94 comes after a strong 30 day share price return of 46.46% and 90 day share price return of 56.80%. The 1 year total shareholder return of 7.34% and 3 year total shareholder return of 43.16% suggest...

DiDi Global Inc. has reported its second-quarter 2026 results, with sales rising to CNY 62,522 million and net income reaching CNY 866 million, marking a shift from a loss a year earlier. An interesting contrast emerges as the company delivered a profitable second quarter while still recording a net loss of CNY 354 million for the first half of 2026. We will now examine how DiDi Global’s return to quarterly profitability, alongside continued first-half losses, shapes the company’s investment...

Anyone interested in RCM Technologies, Inc. ( NASDAQ:RCMT ) should probably be aware that the Division President of...

We wouldn't blame Virtu Financial, Inc. ( NYSE:VIRT ) shareholders if they were a little worried about the fact that...

We wouldn't blame The Procter & Gamble Company ( NYSE:PG ) shareholders if they were a little worried about the fact...

Cinemark Holdings (CNK) is back in focus after announcing that Spider-Man: Brand New Day is now the highest grossing domestic film in its history, with record results in premium formats and related in-theater spending. See our latest analysis for Cinemark Holdings. Cinemark Holdings' latest record for Spider-Man: Brand New Day arrives during a strong run for the stock, with a 30-day share price return of 11.89% and a 90-day gain of 38.48%. The 1-year total shareholder return of 39.64% and...

Pfizer stock has returned 16.1% over the past year after a weaker five year stretch, while the valuation checks and market multiples now point to a mixed picture rather than a clear bargain. The share price is still down 21.5% over 5 years, which suggests longer term holders have not yet fully recovered their losses despite the recent rebound. Regulatory progress on the Lyme disease vaccine candidate and broader interest in mRNA and cancer antibody conjugate therapies can support sentiment,...